Medicare’s Breakthrough Coverage of Weight Loss Drugs
Game-changing GLP-1 benefit launches July 2026.
After years of statutory prohibition, Medicare is making its biggest move yet into obesity treatment. Starting July 1, 2026, the new Medicare GLP-1 Bridge program will give eligible clients access to Medicare weight loss drugs for just $50 a month– lowering costs and improving health. Help clients navigate these exciting new options.
Medicare negotiates 82% price drop on GLP-1 weight loss drugs
The need for GLP-1 medications among seniors is huge and growing. More than two-thirds of Medicare beneficiaries are either overweight (35%) or obese (34%).
Medicare’s negotiating power delivered remarkable results for beneficiaries.
- Massive price drops: The program secured a $245 net price per 30-day supply from makers Novo Nordisk and Eli Lilly.
- Lower out-of-pocket costs: This slashes typical costs that used to range from $1,000 to $1,350 monthly.
- Capped copays: For eligible clients, the copay is capped at just $50.
The Congressional Budget Office projects this coverage could save $3.4 billion in healthcare costs by 2034 by reducing heart events, diabetes complications, and other obesity-related conditions.
What your clients can access
The initial Bridge program covers two medications proven to help with weight reduction: Wegovy® (semaglutide) in both injection and tablet forms, and Zepbound® (tirzepatide). Additional GLP-1 formulations, including Ozempic, Mounjaro, and Rybelsus, will become available when the full BALANCE Model launches in January 2027.
Eligibility made simple
Beneficiaries must be enrolled in a Medicare Part D plan and meet specific clinical criteria:
- BMI ≥35 (no additional conditions required), or
- BMI ≥30 with uncontrolled hypertension, heart failure, or chronic kidney disease, or
- BMI ≥27 with prediabetes or established cardiovascular disease
Their healthcare provider must submit a prior authorization request confirming these details.
Your client conversation strategy
This benefit addresses questions you’re likely already hearing, as 9% of adults 65 and older are currently using GLP-1 medications, and many struggle with the cost. Position this as a significant new Medicare advantage: measurable savings on medications that improve multiple health outcomes.
Key talking points:
- “Medicare negotiated an 82-96% discount on these medications.”
- “Your $50 monthly copay covers the full treatment.”
- “Coverage starts July 1—now is the time to talk with your doctor about eligibility.”
The new Medicare GLP-1 Bridge program runs through December 2026, transitioning to the longer-term BALANCE Model in 2027. Beneficiaries enrolled in the Bridge will need to select a participating Part D plan during the 2027 enrollment period to maintain coverage.
This can be a life-changing benefit for seniors and is a great conversation starter that demonstrates your knowledge and commitment to helping clients navigate Medicare’s evolving landscape.
Key takeaways:
- Coverage start date: The Medicare GLP-1 Bridge program for weight loss drugs officially launches July 1, 2026.
- Eligibility requirements: Clients must be enrolled with Medicare Part D, meet qualifying BMI criteria, and have a provider-submitted prior authorization.
- Cost savings: Medicare negotiated a $245 net price per 30-day supply from Novo Nordisk and Eli Lilly, cutting costs from $1,000 monthly down to a $50 capped copay for eligible clients.
- Initial medications covered: Wegovy® (semaglutide) in injection and tablet forms, plus Zepbound® (tirzepatide).
- Future expansion: Additional GLP-1 options (Ozempic, Mounjaro, Rybelsus) become available in January 2027 under the BALANCE Model.
